All In Biotech

NDA 020533 · Fresenius Kabi USA

Naropin

Ropivacaine Hydrochloride · Injection

Novel

Last checked: Nov 19, 2026Latest source record: Jun 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Sep 24, 1996

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,293

162 Phase 3, 97 recruiting

FAERS reports

2,453

2,216 serious, 127 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 22, 2026.

NAROPIN is indicated for the production of local or regional anesthesia for surgery and for acute pain management. Surgical Anesthesia : epidural block for surgery including cesarean section; major nerve block; local infiltration Acute Pain Management : epidural continuous infusion or intermittent bolus, e.g., postoperative or labor; local infiltration NAROPIN is an amide local anesthetic indicated in adults for the production of local or regional anesthesia for surgery and for acute pain management. (1) Surgical Anesthesia : epidural block for surgery including cesarean section; major nerve block; local infiltration Acute Pain Management : epidural continuous infusion or intermittent bolus, e.g., postoperative or labor; local infiltration

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 2, 2000 Supplement 2 · Efficacy Review
  • Sep 24, 1996 Original approval · Type 1 - New Molecular Entity Review
13 products under this application
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 150MG/30ML (5MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 200MG/100ML (2MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 75MG/10ML (7.5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INJECTION · Discontinued
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 150MG/20ML (7.5MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 1GM/200ML (5MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 40MG/20ML (2MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 500MG/100ML (5MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 400MG/200ML (2MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 50MG/10ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INJECTION · Discontinued
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 100MG/10ML (10MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 200MG/20ML (10MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 100MG/20ML (5MG/ML) · SOLUTION, INJECTION · Prescription · TE AP
  • NAROPIN · ROPIVACAINE HYDROCHLORIDE 20MG/10ML (2MG/ML) · SOLUTION, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ropivacaine" as an intervention, any sponsor and status, largest first.

All 1,293 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting622
  • dyspnoea618
  • pneumonia612
  • drug hypersensitivity607
  • oedema599
  • asthma576
  • wheezing567
  • pain268
  • malaise242
  • respiratory tract infection222
  • chest pain200
  • cough188

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200448
200556
200640
200747
200895
200981
2010102
2011139
2012125
201330
201444
201566
201654
201734
201854
201978
202048
202151
2022161
2023221
2024306
2025342
2026231

Recalls

1 FDA enforcement reports for this application.

  • Jul 16, 2026 · Class II · Ongoing

    Presence of Particulate Matter: Hair was found in products

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23).

  • Current · updated Nov 18, 2026

    Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20). Delay in shipping of the drug

  • Current · updated Nov 18, 2026

    Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21). Check wholesalers for inventory

  • Current · updated Nov 18, 2026

    Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20). Demand increase for the drug

  • Current · updated Nov 18, 2026

    Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11).

  • Current · updated Nov 18, 2026

    Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Naropin* (Ropivacaine HCL/PF*) · HCPCS J2795

2024 spending

$48K

Beneficiaries

9,909

16,024 claims

Per beneficiary

$5

2024 ASP limit $0.07 per unit

View as table
YearSpending
2020$28,823
2021$40,587
2022$48,870
2023$53,356
2024$48,141

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,058 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.